Clinical performance of the TrueMark™ MSI assay for microsatellite instability detection in a Chinese colorectal cancer cohort
•MSI or MMR testing is valuable for assessing prognosis and treatment options in CRC patients, but the conventional detection methods such as IHC are limited by not fully consistent results.•TrueMark™ MSI Assay is a novel solution for MSI analysis, but lack of research support in Chinese CRC patient...
Gespeichert in:
| Veröffentlicht in: | Gene 2024-11, Vol.927, p.148745, Article 148745 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | 148745 |
| container_title | Gene |
| container_volume | 927 |
| creator | Tang, Erjiang Tang, Cui Lin, Xuejing Chen, Ying Zhou, Yi Pan, Chenyu Jiang, Huihong |
| description | •MSI or MMR testing is valuable for assessing prognosis and treatment options in CRC patients, but the conventional detection methods such as IHC are limited by not fully consistent results.•TrueMark™ MSI Assay is a novel solution for MSI analysis, but lack of research support in Chinese CRC patients.•Our results suggested that TrueMark™ MSI provides a fast, reliable and highly automated solution to MSI detection in Chinese CRC patients.
Microsatellite instability (MSI) and mismatch repair (MMR) detection is valuable in assessing prognosis and treatment options. However, the conventional detection methods such as immunohistochemistry (IHC) are limited by not fully consistent results as well as a long turnaround time. TrueMark™ MSI Assay is a novel solution for MSI analysis, but lack of research support in the Chinese colorectal cancer (CRC) patients.
60 dMMR and 60 pMMR CRC samples identified by IHC were collected and their MSI status were detected using TrueMark™ MSI assay with an expanded panel of 13 markers. The overall performance and diagnostic concordance between TrueMark™ MSI test and MMR IHC analysis were assessed and analyzed.
According to the TrueMark™ test, 55 out of the 120 (45.8 %) CRCs were identified as MSI-high (MSI-H) with an instability at ≥ 4/13 markers. Compared with the MMR IHC analysis, an overall percent agreement of 94.2 % and a Kappa of 0.883 were achieved. For the seven inconsistent samples, tumor mutation burden analysis was performed and the results supported the diagnosis by TrueMark™ test. To confirm the robustness of the above findings, a validation was performed in an independent cohort comprising 51 consecutive CRCs. Furthermore, an optimized panel composed of NR-21, NR-24, NR-27, ABI-16, ABI-17 and ABI-20B was developed by multivariate logistic regression model, and showed 100 % agreement with the 13-marker panel for MSI detection in both the derivation and validation sets.
TrueMark™ MSI provides a fast, reliable and highly automated solution to MSI detection in Chinese CRC patients, and the new 6-marker panel we established shows promise deserving further evaluation. |
| doi_str_mv | 10.1016/j.gene.2024.148745 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3153678382</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0378111924006267</els_id><sourcerecordid>3076286797</sourcerecordid><originalsourceid>FETCH-LOGICAL-c255t-c120769cb956af2c64cbb2406ec51d2a34c17c66a925e0b550a78c9b30d08a813</originalsourceid><addsrcrecordid>eNqFkb1uFDEUhS0EIkvgBSiQS5pZ_DP-k2jQioRIiSgIteXx3GG9zIwX2xtpOwqehEfLk-DRBkrixtb1d8-9Ogeh15SsKaHy3W79DWZYM8LaNW21asUTtKJamYYQrp-iFeFKN5RSc4Ze5Lwj9QjBnqMzro00rNUr9HMzhjl4N-I9pCGmyc0ecBxw2QK-TQe4cen7_a_f-ObLFXY5uyOuFJ6CTzG7AuMYCuAw5-K6UN9H3EMBX0KcaxU7vNmGGTJgH8eY6ked5JcZqVa2MZWX6NngxgyvHu5z9PXi4-3mU3P9-fJq8-G68UyI0njKiJLGd0ZINzAvW991rCUSvKA9c7z1VHkpnWECSCcEcUp703HSE-005efo7Ul3n-KPA-Rip5B93d_NEA_Zciq4VJpr9jhaN2FaKqMqyk7oYkdOMNh9CpNLR0uJXUKyO7uEZJeQ7Cmk2vTmQf_QTdD_a_mbSgXenwCohtwFSDb7ANW0PiwW2j6G_-n_AXoFpOs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3076286797</pqid></control><display><type>article</type><title>Clinical performance of the TrueMark™ MSI assay for microsatellite instability detection in a Chinese colorectal cancer cohort</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Tang, Erjiang ; Tang, Cui ; Lin, Xuejing ; Chen, Ying ; Zhou, Yi ; Pan, Chenyu ; Jiang, Huihong</creator><creatorcontrib>Tang, Erjiang ; Tang, Cui ; Lin, Xuejing ; Chen, Ying ; Zhou, Yi ; Pan, Chenyu ; Jiang, Huihong</creatorcontrib><description>•MSI or MMR testing is valuable for assessing prognosis and treatment options in CRC patients, but the conventional detection methods such as IHC are limited by not fully consistent results.•TrueMark™ MSI Assay is a novel solution for MSI analysis, but lack of research support in Chinese CRC patients.•Our results suggested that TrueMark™ MSI provides a fast, reliable and highly automated solution to MSI detection in Chinese CRC patients.
Microsatellite instability (MSI) and mismatch repair (MMR) detection is valuable in assessing prognosis and treatment options. However, the conventional detection methods such as immunohistochemistry (IHC) are limited by not fully consistent results as well as a long turnaround time. TrueMark™ MSI Assay is a novel solution for MSI analysis, but lack of research support in the Chinese colorectal cancer (CRC) patients.
60 dMMR and 60 pMMR CRC samples identified by IHC were collected and their MSI status were detected using TrueMark™ MSI assay with an expanded panel of 13 markers. The overall performance and diagnostic concordance between TrueMark™ MSI test and MMR IHC analysis were assessed and analyzed.
According to the TrueMark™ test, 55 out of the 120 (45.8 %) CRCs were identified as MSI-high (MSI-H) with an instability at ≥ 4/13 markers. Compared with the MMR IHC analysis, an overall percent agreement of 94.2 % and a Kappa of 0.883 were achieved. For the seven inconsistent samples, tumor mutation burden analysis was performed and the results supported the diagnosis by TrueMark™ test. To confirm the robustness of the above findings, a validation was performed in an independent cohort comprising 51 consecutive CRCs. Furthermore, an optimized panel composed of NR-21, NR-24, NR-27, ABI-16, ABI-17 and ABI-20B was developed by multivariate logistic regression model, and showed 100 % agreement with the 13-marker panel for MSI detection in both the derivation and validation sets.
TrueMark™ MSI provides a fast, reliable and highly automated solution to MSI detection in Chinese CRC patients, and the new 6-marker panel we established shows promise deserving further evaluation.</description><identifier>ISSN: 0378-1119</identifier><identifier>ISSN: 1879-0038</identifier><identifier>EISSN: 1879-0038</identifier><identifier>DOI: 10.1016/j.gene.2024.148745</identifier><identifier>PMID: 38969248</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Adult ; Aged ; automation ; Biomarkers, Tumor - genetics ; China ; Cohort Studies ; Colorectal cancer ; colorectal neoplasms ; Colorectal Neoplasms - diagnosis ; Colorectal Neoplasms - genetics ; Concordance ; DNA Mismatch Repair - genetics ; East Asian People ; Female ; genes ; Humans ; immunohistochemistry ; Immunohistochemistry - methods ; Male ; Microsatellite Instability ; microsatellite repeats ; Middle Aged ; Mismatch repair ; mutation ; prognosis ; regression analysis ; research support ; TrueMark</subject><ispartof>Gene, 2024-11, Vol.927, p.148745, Article 148745</ispartof><rights>2024</rights><rights>Copyright © 2024. Published by Elsevier B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c255t-c120769cb956af2c64cbb2406ec51d2a34c17c66a925e0b550a78c9b30d08a813</cites><orcidid>0000-0002-7391-1767 ; 0000-0002-8042-5994</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0378111924006267$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38969248$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tang, Erjiang</creatorcontrib><creatorcontrib>Tang, Cui</creatorcontrib><creatorcontrib>Lin, Xuejing</creatorcontrib><creatorcontrib>Chen, Ying</creatorcontrib><creatorcontrib>Zhou, Yi</creatorcontrib><creatorcontrib>Pan, Chenyu</creatorcontrib><creatorcontrib>Jiang, Huihong</creatorcontrib><title>Clinical performance of the TrueMark™ MSI assay for microsatellite instability detection in a Chinese colorectal cancer cohort</title><title>Gene</title><addtitle>Gene</addtitle><description>•MSI or MMR testing is valuable for assessing prognosis and treatment options in CRC patients, but the conventional detection methods such as IHC are limited by not fully consistent results.•TrueMark™ MSI Assay is a novel solution for MSI analysis, but lack of research support in Chinese CRC patients.•Our results suggested that TrueMark™ MSI provides a fast, reliable and highly automated solution to MSI detection in Chinese CRC patients.
Microsatellite instability (MSI) and mismatch repair (MMR) detection is valuable in assessing prognosis and treatment options. However, the conventional detection methods such as immunohistochemistry (IHC) are limited by not fully consistent results as well as a long turnaround time. TrueMark™ MSI Assay is a novel solution for MSI analysis, but lack of research support in the Chinese colorectal cancer (CRC) patients.
60 dMMR and 60 pMMR CRC samples identified by IHC were collected and their MSI status were detected using TrueMark™ MSI assay with an expanded panel of 13 markers. The overall performance and diagnostic concordance between TrueMark™ MSI test and MMR IHC analysis were assessed and analyzed.
According to the TrueMark™ test, 55 out of the 120 (45.8 %) CRCs were identified as MSI-high (MSI-H) with an instability at ≥ 4/13 markers. Compared with the MMR IHC analysis, an overall percent agreement of 94.2 % and a Kappa of 0.883 were achieved. For the seven inconsistent samples, tumor mutation burden analysis was performed and the results supported the diagnosis by TrueMark™ test. To confirm the robustness of the above findings, a validation was performed in an independent cohort comprising 51 consecutive CRCs. Furthermore, an optimized panel composed of NR-21, NR-24, NR-27, ABI-16, ABI-17 and ABI-20B was developed by multivariate logistic regression model, and showed 100 % agreement with the 13-marker panel for MSI detection in both the derivation and validation sets.
TrueMark™ MSI provides a fast, reliable and highly automated solution to MSI detection in Chinese CRC patients, and the new 6-marker panel we established shows promise deserving further evaluation.</description><subject>Adult</subject><subject>Aged</subject><subject>automation</subject><subject>Biomarkers, Tumor - genetics</subject><subject>China</subject><subject>Cohort Studies</subject><subject>Colorectal cancer</subject><subject>colorectal neoplasms</subject><subject>Colorectal Neoplasms - diagnosis</subject><subject>Colorectal Neoplasms - genetics</subject><subject>Concordance</subject><subject>DNA Mismatch Repair - genetics</subject><subject>East Asian People</subject><subject>Female</subject><subject>genes</subject><subject>Humans</subject><subject>immunohistochemistry</subject><subject>Immunohistochemistry - methods</subject><subject>Male</subject><subject>Microsatellite Instability</subject><subject>microsatellite repeats</subject><subject>Middle Aged</subject><subject>Mismatch repair</subject><subject>mutation</subject><subject>prognosis</subject><subject>regression analysis</subject><subject>research support</subject><subject>TrueMark</subject><issn>0378-1119</issn><issn>1879-0038</issn><issn>1879-0038</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkb1uFDEUhS0EIkvgBSiQS5pZ_DP-k2jQioRIiSgIteXx3GG9zIwX2xtpOwqehEfLk-DRBkrixtb1d8-9Ogeh15SsKaHy3W79DWZYM8LaNW21asUTtKJamYYQrp-iFeFKN5RSc4Ze5Lwj9QjBnqMzro00rNUr9HMzhjl4N-I9pCGmyc0ecBxw2QK-TQe4cen7_a_f-ObLFXY5uyOuFJ6CTzG7AuMYCuAw5-K6UN9H3EMBX0KcaxU7vNmGGTJgH8eY6ked5JcZqVa2MZWX6NngxgyvHu5z9PXi4-3mU3P9-fJq8-G68UyI0njKiJLGd0ZINzAvW991rCUSvKA9c7z1VHkpnWECSCcEcUp703HSE-005efo7Ul3n-KPA-Rip5B93d_NEA_Zciq4VJpr9jhaN2FaKqMqyk7oYkdOMNh9CpNLR0uJXUKyO7uEZJeQ7Cmk2vTmQf_QTdD_a_mbSgXenwCohtwFSDb7ANW0PiwW2j6G_-n_AXoFpOs</recordid><startdate>20241115</startdate><enddate>20241115</enddate><creator>Tang, Erjiang</creator><creator>Tang, Cui</creator><creator>Lin, Xuejing</creator><creator>Chen, Ying</creator><creator>Zhou, Yi</creator><creator>Pan, Chenyu</creator><creator>Jiang, Huihong</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7S9</scope><scope>L.6</scope><orcidid>https://orcid.org/0000-0002-7391-1767</orcidid><orcidid>https://orcid.org/0000-0002-8042-5994</orcidid></search><sort><creationdate>20241115</creationdate><title>Clinical performance of the TrueMark™ MSI assay for microsatellite instability detection in a Chinese colorectal cancer cohort</title><author>Tang, Erjiang ; Tang, Cui ; Lin, Xuejing ; Chen, Ying ; Zhou, Yi ; Pan, Chenyu ; Jiang, Huihong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c255t-c120769cb956af2c64cbb2406ec51d2a34c17c66a925e0b550a78c9b30d08a813</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Aged</topic><topic>automation</topic><topic>Biomarkers, Tumor - genetics</topic><topic>China</topic><topic>Cohort Studies</topic><topic>Colorectal cancer</topic><topic>colorectal neoplasms</topic><topic>Colorectal Neoplasms - diagnosis</topic><topic>Colorectal Neoplasms - genetics</topic><topic>Concordance</topic><topic>DNA Mismatch Repair - genetics</topic><topic>East Asian People</topic><topic>Female</topic><topic>genes</topic><topic>Humans</topic><topic>immunohistochemistry</topic><topic>Immunohistochemistry - methods</topic><topic>Male</topic><topic>Microsatellite Instability</topic><topic>microsatellite repeats</topic><topic>Middle Aged</topic><topic>Mismatch repair</topic><topic>mutation</topic><topic>prognosis</topic><topic>regression analysis</topic><topic>research support</topic><topic>TrueMark</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tang, Erjiang</creatorcontrib><creatorcontrib>Tang, Cui</creatorcontrib><creatorcontrib>Lin, Xuejing</creatorcontrib><creatorcontrib>Chen, Ying</creatorcontrib><creatorcontrib>Zhou, Yi</creatorcontrib><creatorcontrib>Pan, Chenyu</creatorcontrib><creatorcontrib>Jiang, Huihong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><jtitle>Gene</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tang, Erjiang</au><au>Tang, Cui</au><au>Lin, Xuejing</au><au>Chen, Ying</au><au>Zhou, Yi</au><au>Pan, Chenyu</au><au>Jiang, Huihong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical performance of the TrueMark™ MSI assay for microsatellite instability detection in a Chinese colorectal cancer cohort</atitle><jtitle>Gene</jtitle><addtitle>Gene</addtitle><date>2024-11-15</date><risdate>2024</risdate><volume>927</volume><spage>148745</spage><pages>148745-</pages><artnum>148745</artnum><issn>0378-1119</issn><issn>1879-0038</issn><eissn>1879-0038</eissn><abstract>•MSI or MMR testing is valuable for assessing prognosis and treatment options in CRC patients, but the conventional detection methods such as IHC are limited by not fully consistent results.•TrueMark™ MSI Assay is a novel solution for MSI analysis, but lack of research support in Chinese CRC patients.•Our results suggested that TrueMark™ MSI provides a fast, reliable and highly automated solution to MSI detection in Chinese CRC patients.
Microsatellite instability (MSI) and mismatch repair (MMR) detection is valuable in assessing prognosis and treatment options. However, the conventional detection methods such as immunohistochemistry (IHC) are limited by not fully consistent results as well as a long turnaround time. TrueMark™ MSI Assay is a novel solution for MSI analysis, but lack of research support in the Chinese colorectal cancer (CRC) patients.
60 dMMR and 60 pMMR CRC samples identified by IHC were collected and their MSI status were detected using TrueMark™ MSI assay with an expanded panel of 13 markers. The overall performance and diagnostic concordance between TrueMark™ MSI test and MMR IHC analysis were assessed and analyzed.
According to the TrueMark™ test, 55 out of the 120 (45.8 %) CRCs were identified as MSI-high (MSI-H) with an instability at ≥ 4/13 markers. Compared with the MMR IHC analysis, an overall percent agreement of 94.2 % and a Kappa of 0.883 were achieved. For the seven inconsistent samples, tumor mutation burden analysis was performed and the results supported the diagnosis by TrueMark™ test. To confirm the robustness of the above findings, a validation was performed in an independent cohort comprising 51 consecutive CRCs. Furthermore, an optimized panel composed of NR-21, NR-24, NR-27, ABI-16, ABI-17 and ABI-20B was developed by multivariate logistic regression model, and showed 100 % agreement with the 13-marker panel for MSI detection in both the derivation and validation sets.
TrueMark™ MSI provides a fast, reliable and highly automated solution to MSI detection in Chinese CRC patients, and the new 6-marker panel we established shows promise deserving further evaluation.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>38969248</pmid><doi>10.1016/j.gene.2024.148745</doi><orcidid>https://orcid.org/0000-0002-7391-1767</orcidid><orcidid>https://orcid.org/0000-0002-8042-5994</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0378-1119 |
| ispartof | Gene, 2024-11, Vol.927, p.148745, Article 148745 |
| issn | 0378-1119 1879-0038 1879-0038 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3153678382 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Adult Aged automation Biomarkers, Tumor - genetics China Cohort Studies Colorectal cancer colorectal neoplasms Colorectal Neoplasms - diagnosis Colorectal Neoplasms - genetics Concordance DNA Mismatch Repair - genetics East Asian People Female genes Humans immunohistochemistry Immunohistochemistry - methods Male Microsatellite Instability microsatellite repeats Middle Aged Mismatch repair mutation prognosis regression analysis research support TrueMark |
| title | Clinical performance of the TrueMark™ MSI assay for microsatellite instability detection in a Chinese colorectal cancer cohort |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T12%3A14%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20performance%20of%20the%20TrueMark%E2%84%A2%20MSI%20assay%20for%20microsatellite%20instability%20detection%20in%20a%20Chinese%20colorectal%20cancer%20cohort&rft.jtitle=Gene&rft.au=Tang,%20Erjiang&rft.date=2024-11-15&rft.volume=927&rft.spage=148745&rft.pages=148745-&rft.artnum=148745&rft.issn=0378-1119&rft.eissn=1879-0038&rft_id=info:doi/10.1016/j.gene.2024.148745&rft_dat=%3Cproquest_cross%3E3076286797%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3076286797&rft_id=info:pmid/38969248&rft_els_id=S0378111924006267&rfr_iscdi=true |